Eutropics has discovered new diagnostic methods that extend the utility of the Praedicare Dx ™
Eutropics is developing new versions of the Praedicare Dx™ that will extend the medical utility of the platform to solid tumor cancers, which represent a very large percentage of those people afflicted with cancer. The new format is a patent protected technology that probes the predisposition of the cancer cell to respond to apoptosis signaling. We are working with collaborators to establish proof of principle for clinical utility in solid tumors. Our objective is to provide an approved clinical test that will guide the best treatment option selection for a wide range of cancer patients.